
CERE Stock Forecast & Price Target
CERE Analyst Ratings
Bulls say
Cerevel Therapeutics Hldg is poised for success with its differentiated approach to treating neuroscience diseases and its strong portfolio of investigational therapies. The recent acquisition by AbbVie further solidifies Cerevel's position as a leader in this space. With a diverse pipeline and promising results from its clinical trials, Cerevel has the potential for significant growth and is a strong investment opportunity for those interested in the neuroscience sector.
Bears say
Cerevel Therapeutics Hldg is facing significant challenges with a recent downgrade and price target of $45 due to an acquisition by AbbVie. The company's DCF model suggests a decline rate of 10% and a discount rate of 8.3%, which indicates a low valuation of their assets. Additionally, past clinical studies for their investigational therapies have been halted, raising concerns about potential safety and tolerability issues. With limited potential for other suitors and the deal with AbbVie likely to close, there are several uncertainties surrounding Cerevel's future prospects.
This aggregate rating is based on analysts' research of Cerevel Therapeutics Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
CERE Analyst Forecast & Price Prediction
Start investing in CERE
Order type
Buy in
Order amount
Est. shares
0 shares